Hidradenitis Suppurativa Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Hidradenitis Suppurativa Market is Segmented By Clinical Stage (Hurley Stage 1, Hurley Stage 2, Hurley Stage 3), By Skin Condition (Folliculitis, Pimples, Boils, Deep-Acne, Others), By Treatment Type (Surgery, Medications, Photodynamic Therapy (PDT), Laser Treatment, Others), By Route of Administration (Oral, Parenteral, Others), By End-user (Hospitals, Specialty Clinics, Homecare, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Hidradenitis Suppurativa Market Size

The Global Hidradenitis Suppurativa Market reached USD 725.6 million in 2022 and is projected to witness lucrative growth by reaching up to USD 1.1 billion by 2031. The Global Hidradenitis Suppurativa Market is expected to exhibit a CAGR of 4.8% during the forecast period 2024-2031. Apocrine gland-rich regions, such as the armpits, groin, and buttocks, are affected by the chronic inflammatory skin disorder known as hidradenitis suppurative (HS), characterized by painful, recurrent nodules and abscesses. It is a sporadic disease that affects 1% to 4% of the world's population.  

Hidradenitis Suppurativa Market Scope

To know more Insights - Download Sample

Hidradenitis Suppurativa Market Dynamics

Increasing FDA approval of products is driving the Global Hidradenitis Suppurativa Market growth. 

In May 2023, Adalimumab-aaty, a biosimilar of Humira (adalimumab) with a high concentration (100 mg/mL) and no citrate, was given FDA approval, reported by Celltrion USA. Hidradenitis suppurativa, rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis are among the eight illnesses for which the FDA has approved.

Yuflyma is the second anti-TNF biosimilar licensed in the United States and Celltrion's sixth overall biosimilar. Yuflyma will provide patients with pre-filled syringes and autoinjector administration alternatives to accommodate a range of preferences and needs. Patients have a different therapy choice with Yuflyma's high-concentration, citrate-free adalimumab biosimilar formulation. It stands for an effective therapeutic option for patient care and patient choice. 

Increasing research and development activities are driving the Global Hidradenitis Suppurativa Market growth.

For instance, in March 2023, at the American Academy of Dermatology's annual meeting, UCB presented new data showing results from two phases 3 trials testing the drug candidate in hidradenitis suppurativa held up through 48 weeks. In the trials dubbed BE HEARD I and BE HEARD II, bimekizumab previously showed statistically significant results over placebo at Week 16. 

At Week, some patients even cleared the trials' shared primary endpoint, a 50% reduction of skin abscesses and inflammatory nodules. At Week 16 in the trials, 47.8% of patients in BE HEARD I and 52% in BE HEARD II experienced a 50% reduction in skin abscesses and inflammatory nodules. That compared with 28.7% and 32% for placebo, respectively. The patients also experienced “improved” quality of life as scored on a dermatology life-quality index.

The Side effects of hidradenitis suppurativa treatment hamper the Global Hidradenitis Suppurativa Market growth.

The Side effects of hidradenitis suppurativa treatment hamper the global hidradenitis suppurativa market growth. Antibiotics show gastrointestinal symptoms (Nausea, vomiting, diarrhea, abdominal pain), increased sensitivity to sunlight, and prolonged or improper use of antibiotics may lead to the growth of antibiotic-resistant bacteria.

Biologic therapies can suppress the immune system, increasing the risk of infections, redness, swelling, pain, or itching at the injection site. Rarely biologic therapies can cause severe allergic reactions, such as difficulty breathing, swelling, or hives.

Hidradenitis Suppurativa Market Segment Analysis

The Global Hidradenitis Suppurativa Market is segmented based on clinical stage, skin condition, treatment type, route of administration, end-user, distribution channel, and region. 

The medications segment is expected to hold a dominant position in the market over the forecast period.

The medications segment had the highest market stake, accounting for approximately 32.5% of the hidradenitis suppurativa market in 2022. Patients with moderate-to-severe HS have reported a considerable drop in illness flares with the introduction of biologics. 

In two phase III trials, the monoclonal antibody adalimumab, which targets tumor necrosis factor-alpha, showed efficacy compared to placebo, and is now regarded as a first-choice biologic drug when conventional therapy fails. Before beginning biologic treatment, patients may wait several years and travel to ERs and inpatient care facilities.

Source: DataM Intelligence Analysis (2023)

Hidradenitis Suppurativa Market Geographical Share

North America holds a dominant position in the Global Hidradenitis Suppurativa Market.

North America is estimated to hold around 41.1% of the total market share throughout the forecast period. Increasing research and development of hidradenitis suppurativa is expected to boost regional growth over the forecast period. 

For instance, in December 2022, KT-474 (IRAK4) Phase 1 clinical trial patient cohort results were positive. Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, also provided updates on its three oncology programs, KT-413 (IRAKIMiD), KT-333 (STAT3), and KT-253 (MDM2).

Source: DataM Intelligence Analysis (2023)

Hidradenitis Suppurativa Market Companies

The major global players in the market include Pfizer Inc., Eli Lilly and Company, AbbVie Inc., UCB S.A., Incyte Corporation, Novartis AG, Boehringer Ingelheim, Aclaris Therapeutics, Inc., InflaRx N.V., and Moonlake Immunotherapeutics among others.

COVID-19 Impact on Hidradenitis Suppurativa Market

Russia Ukraine Conflict Analysis

The Russia-Ukraine war may affect the hidradenitis suppurativa market due to consumer confidence and purchasing power being impacted during times of geopolitical instability and economic uncertainty. Uncertainty exists on how the conflict will affect regional hidradenitis suppurativa research and development. 

Conflict may cause delays or disruptions in research efforts, collaborations, and clinical trials, which could impede access to clinical trials for afflicted populations or inhibit the discovery of novel medicines. 

Artificial Intelligence Analysis:

Artificial intelligence (AI) is increasingly being used in the hidradenitis suppurativa market to improve various aspects of the customer experience. AI algorithms that analyze medical images, such as dermatoscopic or histological images, can help in the diagnosis and classification of HS lesions. Accurately recognizing HS lesions and separating them from other skin disorders can be aided by AI models that have been trained on huge datasets. 

Patients with HS can receive information, assistance, and direction through chatbots or virtual assistants powered by AI. To aid patients in efficiently managing their disease, these virtual assistants can respond to frequently requested queries, give educational materials, and make lifestyle suggestions.

By Clinical Stage

• Hurley Stage 1
• Hurley Stage 2
• Hurley Stage 3

Skin Condition

• Folliculitis
• Pimples
• Boils
• Deep-Acne
• Others

Treatment Type

• Surgery
• Medications
  • Biologics
  • Antibiotics
  • Hormonal Therapy
  • Immunosuppressive Drugs
  • Zinc Supplements
  • Retinoids
  • Pain Medication
  • Others
• Photodynamic Therapy (PDT)
• Laser Treatment
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • The U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• In March 2023, UCB, the biopharmaceutical company, released detailed encouraging results in two Phase 3 studies (BE HEARD I and BE HEARD II) investigating the efficacy and safety of bimekizumab in the treatment of people with moderate to severe hidradenitis suppurative (HS). 

Data from the two studies revealed that bimekizumab, compared to placebo, significantly and consistently improved the signs and symptoms of HS at week 16 and continued to do so until week 48. From the first dose of bimekizumab, clinical responses were seen, with some patients achieving HiSCR50 by week four.

• In February 2023, MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on developing next-level therapies for inflammatory diseases, reported that the global Phase 2 clinical trial evaluating sonelokimab in moderate-to-severe hidradenitis suppurative has enrolled the target 210 patients randomized ahead of schedule.

Why Purchase the Report?

• To visualize the global hidradenitis suppurativa market segmentation based on the clinical stage, skin condition, treatment type, route of administration, end-user, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.  
• Excel data sheet with numerous hidradenitis suppurativa market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Hidradenitis Suppurativa Market Report Would Provide Approximately 85 Tables, 93 Figures And 200+ Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies